Quality of Life Is an Important Endpoint in Cancer Trials

Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials.

Health-related quality of life (QOL) is becoming an increasingly important endpoint in cancer clinical trials, explained Giuseppe Lombardi, MD, PhD, a medical oncologist at the Veneto Institute of Oncology in Padua, Italy.

It is important that clinicians can offer patients not only the chance of improved survival, but also to live well in the meantime. This is especially true for patients with glioblastoma, who can have decreased neurologic or physical functioning. To ensure this, cancer treatment centers should assemble multidisciplinary teams that involve psychosocial supports, therapists, and more.

Related Videos
Karyn Goodman
Grace Choong
Ahulwalia on Targeting the Blood Brain Barrier With Novel Immunotherapies and Precision Oncology
Verina on Tackling Neurological Toxicities From CAR T-Cell Therapy
Paula Anastasia Emphasizes Importance of Genetic Testing in Selecting Maintenance
Laura Wood on the Integration of Avelumab, Erdafitinib, and Enfortumab Vedotin into Urothelial Cancer Care
Paula Anastasia on PARP Inhibitor Ineligibility Factors for Women With Ovarian Cancer
Beth Sandy on Incorporating Amivantamab and Mobocertinib into Clinical Practice for Patients With EGFR Exon 20 Insertion NSCLC
Kelley Rone on the Evolving Role of Immunotherapy in GI Cancers
Related Content
© 2023 MJH Life Sciences

All rights reserved.